The genetic alterations in the oncogenic pathway of transitional cell carcinoma of the bladder and its prognostic value

Urological Research

Volumn 29, Issue 6, 2001, Pages 377-387

  Gontero, Paolo ^a,b   Tizzani, Alessandro ^a,b   Muir, Gordon H ^b,c   Caldarera, Emanuele ^b,d   Pavone Macaluso, Michele ^b,d  

^a UNIVERSITY OF TURIN   (Italy)

^b King's College Hospital ^*  (Italy)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

Growth factor; Growth factor receptor; Oncogenes; RAS; SRC; Transcription factor; Transitional cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

BLADDER CARCINOMA; CANCER STAGING; CELL CYCLE; CELL PROLIFERATION; EXTRACELLULAR SPACE; GENE ACTIVATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, TRANSITIONAL CELL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ONCOGENES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 0035674306     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002400100216     Document Type: Review

References (81)

1. A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation
2. Evaluation of epidermal growth factor receptors in bladder tumours
3. Transitional cell carcinoma of the renal pelvis and its expression of p53 protein, c-erbB-2 protein, neuron-specific enolase, PHE 5, chromogranin, laminin and collagene type IV
4. Ras oncogenes in human cancers: A review
5. Frequency of H-ras mutations in human bladder cancer detected by direct sequencing
6. c-src protein kinase is an early event in colonic carcinogenesis
7. Overexpression and amplification of the c-myc gene in human urothelial carcinoma
8. A simple method to reveal possible ras mutations in DNA of urinary sediment cells
9. Differential hypomethylation of the c-myc proto-oncogene in bladder cancers at different stages and grades
10. The neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients
11. Correlation between the expression of oncogene ras and c-erb-B-2 and the biological behavior of bladder tumor
12. Expression of transforming growth factor beta-1, beta-2 and beta-3 in human bladder carcinomas
13. The role of c-myc in cell growth
14. c-src in low grade human bladder carcinomas
15. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors
16. Evaluation of c-RAS oncogene product (p21) in superficial bladder cancer
17. Oncogenes and tumor suppressor genes
18. Expression of epidermal growth factor (EGF) and the EGF receptor in human tissues
19. Frequency of molecular alterations affecting ras proto-oncogenes in human urinary tract tumors
20. Epidermal growth factor in urine from patients with urothelial tumors
21. High levels of transforming growth factor-alpha (TGF-alpha) mRNA may predict local relapses in early stage urinary bladder cancer
22. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and erbB2 gene product in transitional cell carcinoma of urinary bladder: A study in Greek patients
23. Immunodetection of the p21 ras product in human normal and preneoplastic tissues and solid tumours: A review
24. DNA microarrays for analysis of gene expression
25. Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence of the urinary bladder
26. p53 and p53-regulated genes in bladder cancer
27. Mutation of H-ras is infrequent in bladder cancer: Configuration by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms and direct sequencing
28. Role of myc amplification and overexpression in cell growth, differentiation and death
29. Epidermal growth factor in urine from patients with urinary bladder tumors
30. The loss of retinoblastoma gene in association with c-myc and transforming growth factor βl gene expression in human bladder cancer
31. Effect of urine of clonal growth of human bladder cancer cell lines
32. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorilation
33. HER2 cytoplasmatic domain generate normal mitogenic and transforming signals in a chimeric receptor
34. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
35. Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer
36. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer
37. Expression of epidermal growth factor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis
38. Prognostic value of MIB-1 score, p53, EGEr, mitotic index and papillary status in primary superficial (stage pTa-T1) bladder cancer: A prospective comparative study
39. C-myc oncoprotein levels in bladder cancer
40. Urinary epidermal growth factor concentrations in various human malignancies
41. Transforming growth factor-α levels in bladder cancer and their relationship to epidermal growth factor receptor
42. C-erbB-2 in ladder cancer: Molecular biology, correlation with epidermal growth factor receptors and prognostic value
43. Growth factors and human bladder tumours
44. Epidermal growth factor and its receptor: Markers of- and targets for chemoprevention of bladder cancer
45. Human bladder and colon carcinomas contain activated fas p21
46. p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer
47. Epidermal growth factor receptors in human bladder cancer: Comparison of invasive and superficial tumors
48. The epidermal growth factor receptor and the prognosis in bladder cancer
49. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder: A multivariate survival analysis
50. Ha-ras codon 12 mutation in papillary tumors of the urinary bladder: A retrospective study
51. Detection of ERB-2 amplification in transitional cell bladder carcinoma using competitive PCR technique
52. Expression of transforming growth factor alpha and epidermal growth factor receptor in human bladder cancer
53. DNA hypomethylation and differentiation in Friend leukemia cell variants
54. Oncogenes in solid tumors
55. Oncogenes in human tumor cell lines: Molecular cloning of a transforming gene from human bladder carcinoma cells
56. Expression of the type 1 tyrosine kinase growth factor receptors EGF receptor, c-erbB-2 and c-erbB-3 in bladder cancer
57. Evaluation of epidermal growth factor receptor, transforming growth factor α, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer
58. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene
59. -src protein kinase activity in human tumor cell lines and tissue
60. Screening of H-ras gene point mutations in 50 cases of bladder carcinoma
61. Abnormal c-myc oncogene DNA methylation in human bladder cancer: Possible role in tumor progression
62. Molecular genetic alterations of c-myc oncogene in superficial and locally advanced bladder cancer
63. C-myc copy number gain in bladder cancer detected by fluorescence in situ hybridization
64. C-myc in bladder cancer. Clinical findings and analysis of mechanisms
65. Control of c-myc regulation in normal and neoplastic cells
66. Epidermal growth receptor expression: Predictive value for the outcome after cystectomy for bladder cancer?
67. c-erbB-2 (HER-2/ neu) oncopeptide immunoreactivity in localized high grade transitional cell carcinoma of the bladder
68. C-jun oncogene expression in transitional cell carcinoma of the urinary bladder
69. Correlation between the expression of the p21 ras oncogene product and biological behavior of bladder tumor
70. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients
71. Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer
72. Infrequent involvement of mutations on Neurophibromatosis type 1, H-ras, K-ras and N-ras in urothelial tmours
73. Ras oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma
74. Roles for transforming growth factor-β in the genesis, prevention and treatment of breast cancer
75. Patterns of p53, erbB-2 and EGFr expression in premalignant lesions of the urinary bladder
76. Evaluation of epidermal growth factor receptor DNA amplification and mRNA expression in bladder cancer
77. Expression of p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human bladder
78. Similarity of protein encoded by the human erbB2 gene to epidermal growth factor receptor
79. Transforming growth factor beta-1 induced changes in cell migration, proliferation and angiogenesis in the chicken chorioallantoic membrane